Month: November 2022

Arun Kumar, V. A. published the artcileInsights into binding of potential antitumor quinoxaline analogues against Cyclin dependent kinase 2 using docking studies, Recommanded Product: 2,3,6,7-Tetrachloroquinoxaline, the main research area is quinoxaline analog anticancer CDK2 therapeutic target mol docking cancer.

Cyclin-dependent kinases (CDKs) belongs to a family of protein kinases and CDK2 considered as potential anti-cancer target among CDKs. A CDK2 inhibitor is a chem. that inhibits the function of CDKs and prevents over proliferation of cancer cells thus used to treat cancers. Quinoxaline and its derivatives are an important class of benzoheterocycles displaying a broad spectrum of biol. activities which have made them privileged structures in pharmacol. active compounds Modification in their structure has offered a high degree of diversity that has proven useful for the development of new therapeutic agents having improved potency and lesser toxicity. In the present work, attempts were made to identify leading quinoxaline moieties as candidate drugs against CDK2 by carrying out docking experiments with our inhouse synthetic 46 analogs and assigning docking scores. Ten moieties with docking score -5 or above were zoomed in as candidate moieties. Structural features of the above quinoxaline analogs will be presented with a view to arrive at potential drug target for CDK2.

Journal of Chemical, Biological and Physical Sciences published new progress about Antitumor agents. 25983-14-6 belongs to class quinoxaline, name is 2,3,6,7-Tetrachloroquinoxaline, and the molecular formula is C8H2Cl4N2, Recommanded Product: 2,3,6,7-Tetrachloroquinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Harsha, Kachigere B. published the artcileAn Easy and Efficient Method for the Synthesis of Quinoxalines Using Recyclable and Heterogeneous Nanomagnetic-Supported Acid Catalyst under Solvent-Free Condition, Computed Properties of 40353-41-1, the main research area is quinoxaline preparation solvent free green chem anticancer human; diketone ortho phenylenediamine cyclocondensation nanocatalyst.

Synthesis of quinoxalines from o-phenylenediamines (o-PDs) with electronically diversified 1,2-diketones and α-bromoketones via simple cyclocondensation reaction using an heterogeneous nano-gamma-Fe2O3-SO3H catalyst has been reported under solvent free condition. Low cost, easy workup, high yield, operational simplicity, less reaction time, environmentally benign nature and catalyst is magnetically retrievable and can be reused up to five catalytic cycles without significant loss in the product yields are the noteworthy features of this protocol.

ChemistrySelect published new progress about Antitumor agents. 40353-41-1 belongs to class quinoxaline, name is 2-(Thiophen-2-yl)quinoxaline, and the molecular formula is C12H8N2S, Computed Properties of 40353-41-1.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Kumar, K. Shiva published the artcileAlCl3-mediated heteroarylation-cyclization strategy: one-pot synthesis of fused quinoxalines containing the central core of Lamellarin D, Application of 2,3-Dichloro-6-methylquinoxaline, the main research area is pyranoindole quinoxaline preparation enzyme antitumor; indole acid quinoxaline heteroarylation cyclization.

An inexpensive, practical and one-pot method has been developed for the synthesis of quinoxalines fused with pyrano[3,4-b]indole, I (R = H, CH3; R1 = H, CH3; R2 = H, CH3; R3 = H, F, CH3; R4 = H, CH3, CH2CH3, CH2=CHCH2) the central core of Lamellarin D. The methodol. involved construction of the central pyranone ring via an AlCl3-mediated heteroarylation-cyclization method. A number of compounds I are prepared by using this methodol., some of which were converted to the corresponding indol-3-ylquinoxaline derivatives II (R = H, CH3; R1 = H; R2 = H, CH3; R3 = H, CH3; R4 = H, CH2CH3). Several of the pyrano[3,4-b]indole fused quinoxalines I showed promising growth inhibition of cervical and lung cancer cells and good interactions with topoisomerase I in silico.

RSC Advances published new progress about Antitumor agents. 39267-05-5 belongs to class quinoxaline, name is 2,3-Dichloro-6-methylquinoxaline, and the molecular formula is C9H6Cl2N2, Application of 2,3-Dichloro-6-methylquinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Thabit, Mohamed G. published the artcileSynthesis and biological evaluation of new 3-(4-substituted phenyl)aminoquinoxaline derivatives as anticancer agents, Recommanded Product: 2,3-Dichloro-6-methylquinoxaline, the main research area is phenylaminoquinoxaline preparation anticancer mol modeling human.

Quinoxaline derivatives e.g. I, were synthesized and evaluated for their in vitro growth inhibitory activities against liver carcinoma cell line (HEPG2) using the sulforhodiamine B assay. The synthesis was achieved by reaction of 2,3-dichloroquinoxalines with 4-aminoacetophenone to give the corresponding 2-(4-acetylphenylamino)-3-quinoxaline derivatives Claisen-Schmidt condensation reaction of these quinoxaline derivatives with furfuraldehyde gave enones, which were transformed into pyridines, isoxazolines, pyrazolines, and pyrimidines via several synthetic routes. Virtual screening was carried out by mol. modeling evaluation of the designed compounds Biol. evaluation of the prepared compounds showed that most of the synthesized compounds exhibit more than 50% growth inhibitory.

Heterocyclic Communications published new progress about Antitumor agents. 39267-05-5 belongs to class quinoxaline, name is 2,3-Dichloro-6-methylquinoxaline, and the molecular formula is C9H6Cl2N2, Recommanded Product: 2,3-Dichloro-6-methylquinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Lee, Young Bok published the artcileSynthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives, Recommanded Product: 2,3-Dichloro-6-methylquinoxaline, the main research area is preparation anticancer piperazine derivative drug bioavailability.

Based on the anticancer activity of novel quinoxalinyl-piperazine compounds, 1-[(5 or 6-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives published in Bioorganic Med. Chem.2010, 18, 7966, we further explored the synthesis of 7 or 8-substituted quinoxalinyl piperazine derivatives From in vitro studies of the newly synthesized compounds using human cancer cell lines, we identified some of the 8-substituted compounds, for example 6p, 6q and 6r, which inhibited the proliferation of various human cancer cells at nanomolar concentrations Compound 6r, in particular, showed the lowest IC50 values, ranging from 6.1 to 17 nM, in inhibition of the growth of cancer cells, which is better than compound 6k (compound 25 in the reference cited above). In order to select and develop a leading compound among the quinoxaline compounds with substitutions on positions 5, 6, 7 or 8, the compounds comparable to compound 6k in in vitro cancer cell growth inhibition were chosen and their pharmacokinetic properties were evaluated in rats. In these studies, compound 6k showed the highest oral bioavailability of 83.4%, and compounds 6j and 6q followed, with 77.8% and 57.6%, resp. From the results of in vitro growth inhibitory activities and the pharmacokinetic study, compound 6k is suggested for further development as an orally deliverable anticancer drug.

Bioorganic & Medicinal Chemistry published new progress about Antitumor agents. 39267-05-5 belongs to class quinoxaline, name is 2,3-Dichloro-6-methylquinoxaline, and the molecular formula is C9H6Cl2N2, Recommanded Product: 2,3-Dichloro-6-methylquinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Nakhi, Ali published the artcileTransition metal free hydrolysis/cyclization strategy in a single pot: synthesis of fused furo N-heterocycles of pharmacological interest, SDS of cas: 39267-05-5, the main research area is chloroquinoxaline alkynyl hydrolysis cyclization; furoquinoxaline preparation sirtuins inhibitory activity; furopyrazine preparation sirtuins inhibitory activity.

A transition metal free tandem two-step strategy has been developed involving hydrolysis of 2-chloro-3-alkynyl quinoxalines/pyrazines followed by in situ cyclization of the corresponding 2-hydroxy-3-alkynyl intermediates in a single pot leading to fused furo N-heterocycles as potential inhibitors of sirtuins. A representative compound I showed promising pharmacol. properties in vitro and in vivo.

Organic & Biomolecular Chemistry published new progress about Antitumor agents. 39267-05-5 belongs to class quinoxaline, name is 2,3-Dichloro-6-methylquinoxaline, and the molecular formula is C9H6Cl2N2, SDS of cas: 39267-05-5.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Harsha, Kachigere B. published the artcileOne-step approach for the synthesis of functionalized quinoxalines mediated by T3P-DMSO or T3P via a tandem oxidation-condensation or condensation reaction, Related Products of quinoxaline, the main research area is phenyldiamine hydroxyketone propylphosphonic anhydride tandem oxidation condensation quinoxaline preparation; bromoketone phenyldiamine propylphosphonic anhydride tandem oxidation condensation quinoxaline preparation; diketone phenyldiamine propylphosphonic anhydride condensation quinoxaline preparation; quinoxaline preparation structure activity relationship antitumor activity.

An easy and efficient propylphosphonic anhydride (T3P)-DMSO or T3P mediated oxidation-condensation or condensation reaction for the synthesis of quinoxalines derived from the interaction of different arrays of condensing partners with ortho-phenylene diamines (o-PDs) under simple and mild reaction conditions in one step were reported for the first time.

RSC Advances published new progress about Antitumor agents. 40353-41-1 belongs to class quinoxaline, name is 2-(Thiophen-2-yl)quinoxaline, and the molecular formula is C12H8N2S, Related Products of quinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Lee, Young Bok published the artcileSynthesis and anticancer activity of new 1-[(5 or 6-substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives, Related Products of quinoxaline, the main research area is anticancer quinoxalinyl piperazine derivative preparation SAR.

A series of novel quinoxalinyl-piperazine compounds, 1-[(5 or 6-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives were synthesized and evaluated as an anticancer agent. From screening of quinoxalinyl-piperazine compound library, we identified that many compounds inhibited proliferation of various human cancer cells at nanomolar concentrations Among them, one of the fluoro quinoxalinyl-piperazine derivatives, 25 (I), showed its IC50 values ranging from 11 to 21 nΜ in the growth inhibition of cancer cells. This compound also displayed a more potent effect than paclitaxel against paclitaxel resistant HCT-15 colorectal carcinoma cells. The potency of this novel compound was further confirmed with the synergistic cytotoxic effect with several known cancer drugs such as paclitaxel, doxorubicin, cisplatin, gemcitabine or 5-fluorouracil in cancer cells. This strong cell killing effect was derived from the induction of apoptosis. Mechanistic studies have shown that this quinoxalinyl-piperazine compound is a G2/M-specific cell cycle inhibitor and inhibits anti-apoptotic Bcl-2 protein with p21 induction. Thus the results suggest that our compound has potential use in the growth inhibition of drug resistant cancer cells and the combination therapy with other clin. approved anticancer agents as well.

Bioorganic & Medicinal Chemistry published new progress about Antitumor agents. 39267-05-5 belongs to class quinoxaline, name is 2,3-Dichloro-6-methylquinoxaline, and the molecular formula is C9H6Cl2N2, Related Products of quinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Yang, Yanchun published the artcileAn Efficient Synthesis of Quinoxalinone Derivatives as Potent Inhibitors of Aldose Reductase, SDS of cas: 39267-05-5, the main research area is oxoquinoxalinylacetic acid phenoxy anilino preparation aldose reductase inhibitor; quinoxalinone phenoxy anilino preparation aldose reductase inhibitor.

A novel and facile synthesis of quinoxalinone derivatives was developed in which a wide range of 3-chloroquinoxalin-2(1H)-ones as key intermediates can be generated chemo- and regioselectively in good yields from corresponding quinoxaline-2,3(1H,4H)-diones. This new protocol is arguably superior, as it allows the design and preparation of a variety of bioactive quinoxaline-based compounds, which are particularly effective in the treatment of diabetes and its complications. Through this procedure, a new class of quinoxalinone-based aldose reductase inhibitors were synthesized successfully. Most of the inhibitors, with an N1-acetic acid head group and a substituted C3-phenoxy side chain, proved to be potent and selective. Their IC50 values ranged from 11.4 to 74.8 nM. Among them, 2-(3-(4-bromophenoxy)-7-fluoro-2-oxoquinoxalin-1(2H)-yl)acetic acid and 2-(6-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid were the most active. Structure-activity relationship and mol. docking studies highlighted the importance of the ether spacer in the C3-phenoxy side chains, and provided clear guidance on the contribution of substitutions both at the core structure and the side chain to activity.

ChemMedChem published new progress about Molecular docking. 39267-05-5 belongs to class quinoxaline, name is 2,3-Dichloro-6-methylquinoxaline, and the molecular formula is C9H6Cl2N2, SDS of cas: 39267-05-5.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider

Yang, Yanchun published the artcileAn Efficient Synthesis of Quinoxalinone Derivatives as Potent Inhibitors of Aldose Reductase, Recommanded Product: 2,3,6,7-Tetrachloroquinoxaline, the main research area is oxoquinoxalinylacetic acid phenoxy anilino preparation aldose reductase inhibitor; quinoxalinone phenoxy anilino preparation aldose reductase inhibitor.

A novel and facile synthesis of quinoxalinone derivatives was developed in which a wide range of 3-chloroquinoxalin-2(1H)-ones as key intermediates can be generated chemo- and regioselectively in good yields from corresponding quinoxaline-2,3(1H,4H)-diones. This new protocol is arguably superior, as it allows the design and preparation of a variety of bioactive quinoxaline-based compounds, which are particularly effective in the treatment of diabetes and its complications. Through this procedure, a new class of quinoxalinone-based aldose reductase inhibitors were synthesized successfully. Most of the inhibitors, with an N1-acetic acid head group and a substituted C3-phenoxy side chain, proved to be potent and selective. Their IC50 values ranged from 11.4 to 74.8 nM. Among them, 2-(3-(4-bromophenoxy)-7-fluoro-2-oxoquinoxalin-1(2H)-yl)acetic acid and 2-(6-bromo-3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid were the most active. Structure-activity relationship and mol. docking studies highlighted the importance of the ether spacer in the C3-phenoxy side chains, and provided clear guidance on the contribution of substitutions both at the core structure and the side chain to activity.

ChemMedChem published new progress about Molecular docking. 25983-14-6 belongs to class quinoxaline, name is 2,3,6,7-Tetrachloroquinoxaline, and the molecular formula is C8H2Cl4N2, Recommanded Product: 2,3,6,7-Tetrachloroquinoxaline.

Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider